

The Bleed Beyond Menopause: A Hidden Chapter in Women's Health - A Narrative Review

Dr. R. Subashini¹, Y. Sneha², C. Shifa Sidhiq Fatima³, C. Rifa Sidhik Fathima⁴, V. Sandhiya⁵ and B. Rashmi Avanticaa⁶

¹HOD, Department of Pharmacy Practice, Swamy Vivekanandha College of Pharmacy, INDIA.

²⁵th Pharm D, Department of Pharmacy Practice, Swamy Vivekanandha College of Pharmacy, INDIA.

³⁵th Pharm D, Department of Pharmacy Practice, Swamy Vivekanandha College of Pharmacy, INDIA.

⁴⁵th Pharm D, Department of Pharmacy Practice, Swamy Vivekanandha College of Pharmacy, INDIA.

⁵⁵th Pharm D, Department of Pharmacy Practice, Swamy Vivekanandha College of Pharmacy, INDIA.

⁶⁵th Pharm D, Department of Pharmacy Practice, Swamy Vivekanandha College of Pharmacy, INDIA.

¹Corresponding Author: dr.subashinipharm14@gmail.com



www.jrasb.com || Vol. 4 No. 4 (2025): August Issue

Received: 20-07-2025

Revised: 24-07-2025

Accepted: 29-07-2025

ABSTRACT

Postmenopausal bleeding (PMB), defined as any uterine bleeding occurring after 12 months of amenorrhea, remains a key clinical concern requiring thorough assessment. Although the majority of cases arise from benign conditions such as endometrial atrophy, polyps, or hormone-related effects, PMB can also be an early indicator of gynecologic malignancies, particularly endometrial and cervical cancers. The risk of malignancy increases with advancing age and is influenced by factors such as obesity, diabetes, hypertension, and prolonged exposure to unopposed estrogen.

This narrative review discusses the diverse etiologies of PMB, outlines current diagnostic strategies, and reviews associated histopathological findings and management options. Transvaginal ultrasonography (TVUS) is the preferred initial modality, with endometrial thickness thresholds guiding further intervention. In cases where the endometrium measures ≥ 5 mm or presents with irregularities, additional evaluation through biopsy or hysteroscopy is warranted. Histologic patterns commonly include atrophic changes, polyps, hyperplasia, and, in a subset of patients, carcinoma.

An interdisciplinary approach—integrating gynecologists, radiologists, pathologists, and clinical pharmacists—is essential to improve diagnostic accuracy and treatment outcomes. Clinical pharmacists contribute by reviewing medication profiles, managing hormonal therapies, and supporting adherence.

In conclusion, PMB should never be dismissed as trivial. Early recognition, systematic evaluation, and coordinated care are critical to identifying underlying pathology and improving prognostic outcomes in postmenopausal women.

Keywords- postmenopausal bleeding, endometrial cancer, endometrial biopsy, transvaginal ultrasonography, hormonal therapy.

I. INTRODUCTION

Postmenopausal bleeding (PMB) is defined as vaginal bleeding occurring after a woman has experienced 12 consecutive months without menstruation, indicating the end of natural reproductive function. Though PMB is seen in only 4–11% of postmenopausal individuals, it remains a significant concern and accounts for around 5% of all gynecology outpatient visits [1].

The etiology of PMB spans a broad range, from harmless causes to serious diseases. The most prevalent cause is endometrial or vaginal atrophy, due to estrogen deficiency, which accounts for up to 60–80% of cases [2]. Other common causes include polyps, hyperplasia, hormone therapy, and malignancies, especially endometrial and cervical cancers [2]. While the majority of PMB cases are benign, malignancy must always be ruled out. A landmark study found that nearly 48% of women with PMB were diagnosed with cancer—

predominantly endometrial or cervical—many at advanced stages [3]. Rubin also highlighted that 1 in 5 cases of PMB in older women may be cancer-related [4]. The probability of detecting malignancy in PMB increases with age. For example, while women under 50 have a roughly 1% risk of endometrial cancer, the risk escalates to 24% for women over 80 years [5]. In addition, risk factors such as obesity, diabetes mellitus, hypertension, nulliparity, and late menopause further elevate the chance of endometrial pathology [6,7]. Recurrent PMB, which occurs in 6–25% of women after an initial bleeding episode, is often linked to benign causes like polyps, but still requires investigation due to the potential for underlying cancer [5,8].

Transvaginal ultrasonography (TVS) is the preferred initial diagnostic tool for assessing the endometrium in PMB. Measurement of endometrial thickness (ET) is central to this process. An ET of ≥ 5 mm is generally used as a threshold for further diagnostic testing, including biopsy or hysteroscopy. This cut-off demonstrates a sensitivity of over 90% for detecting endometrial malignancies, although specificity may be reduced in women using hormone replacement therapy (HRT) [9]. Despite the diagnostic value of TVS, hysteroscopy is considered the gold standard for direct evaluation of the endometrial cavity, offering both precise visualization and the option for targeted biopsy or intervention [10].

In conclusion, although many cases of PMB arise from benign processes, the symptom warrants careful evaluation due to the risk of underlying cancer. Early and accurate assessment using a combination of clinical history, imaging, and histological confirmation is essential. With increasing age and a rising burden of gynecologic cancers, structured management of PMB is crucial for timely diagnosis and improved patient outcomes.

II. ETIOLOGY

1. **Atrophic endometrium** – This remains the most frequent cause of PMB. Bleeding is usually mild and self-limited, resulting from the thinning and increased fragility of the endometrial lining following menopause [1–3,9].
2. **Focal endometrial lesions** – These include endometrial polyps, localized hyperplasia, and small, focally growing endometrial cancers. Such lesions are now increasingly identified as important contributors, especially in patients experiencing repeated episodes of bleeding [1,8].
3. **Endometrial hyperplasia (with or without atypia)** – frequently arises from sustained stimulation by unopposed estrogen. This condition is more common in women with risk factors like obesity, diabetes, and metabolic syndrome [4,9].
4. **Endometrial carcinoma** – The risk of malignancy rises with age, higher BMI, diabetes, hypertension,

absence of childbirth (nulliparity), and later age at menopause [3,4,9].

5. **Cervical causes** – Lesions such as cervical polyps or cervical cancer can also result in PMB, sometimes even when imaging shows a thin endometrial lining [4,8].
6. **Hormone-related medications and supplements** – The use of hormone replacement therapy, especially without adequate progesterone, as well as tamoxifen and herbal supplements containing phytoestrogens, can stimulate the endometrium and cause bleeding [1,4].
7. **Other benign uterine conditions** – Examples include submucosal fibroids and hormone-secreting ovarian tumors, which may increase circulating estrogen and lead to endometrial stimulation and bleeding [4,9].
8. **Age-related vascular changes** – Bleeding can also originate from sclerosis and increased fragility of uterine blood vessels in the atrophic uterus [4].
9. **Non-gynecological sources** – In some instances, apparent uterine bleeding may, in reality, originate from the urinary tract or rectum, resulting in misidentification as vaginal bleeding [4]. A graphical representation of the major etiologies of postmenopausal bleeding is illustrated in Fig. 1




Fig. 1: Distribution of common etiologies of postmenopausal bleeding (PMB) among postmenopausal women postmeno

III. PATHOPHYSIOLOGY

Postmenopausal bleeding (PMB) refers to any vaginal bleeding that happens after a woman has gone 12 months without menstruation. Although often caused by non-serious conditions, it can also signal underlying malignancies, making understanding its causes essential for proper diagnosis and care.

1. **Endometrial Atrophy and Fragile Blood Vessels** – After menopause, oestrogen levels drop sharply, leading to thinning and shrinkage of the endometrial lining. This thin endometrium becomes delicate and vulnerable to small injuries or spontaneous bleeding, even without any visible abnormality. As a result, endometrial atrophy is the most frequently identified reason for PMB [1,2]. Aging-related

changes like hardening of uterine blood vessels can also contribute to bleeding in these cases [3].

2. **Excess Oestrogen Without Progesterone** - In some postmenopausal women, especially those who are overweight, oestrogen is still produced in small amounts through conversion of androgens in body fat. When oestrogen acts on the endometrium without being balanced by progesterone, it can cause abnormal thickening of the uterine lining (hyperplasia), which may progress to cancer over time [4,5]. Similarly, using hormone replacement therapy (HRT) with oestrogen alone increases this risk if progesterone is not added for protection [6].
3. **Local Growths in the Uterus** - Polyps growing from the cervix or endometrium can also be a source of bleeding. These benign growths often contain fragile blood vessels that may rupture, leading to spotting or heavier bleeding. Polyps are found in up to 12% of PMB cases and, although usually harmless, can occasionally carry cancerous cells [2,7]. Fibroids, especially those located near the endometrial cavity, may also cause bleeding due to surface irritation or degeneration [2].
4. **Hormone-Producing Tumours and Systemic Illnesses** - Rare tumours of the ovary, such as granulosa cell tumours, may produce oestrogen and mimic the hormonal conditions seen before menopause. This can lead to abnormal growth of the endometrium and PMB [8]. Bleeding can also be worsened by blood disorders, anticoagulant medications, or liver disease, even when the uterine lining appears normal [2].
5. **Malignant Conditions** - Endometrial cancer is the most concerning diagnosis in women with PMB. It is the most common gynaecological cancer after menopause, with abnormal bleeding being its earliest and most frequent symptom. Around 90–95% of women with this cancer experience PMB during its early stages [9]. Although less common, cervical cancer can also cause bleeding, particularly when it invades nearby blood vessels or tissues [3,10]. Risk factors like obesity, high blood pressure, diabetes, infertility, and late menopause increase the chances of malignancy in women with PMB [5,6].

IV. HISTOPATHOLOGY OF POSTMENOPAUSAL BLEEDING (PMB)

1. Atrophic Endometrium

Atrophic endometrium remains predominantly observed histopathological finding in women presenting with postmenopausal bleeding microscopically it is defined by sparse shrunken tubular glands surrounded by dense fibrous stroma and a slender delicate mucosal surface this structural fragility predisposes to spontaneous superficial erosions and rupture of small

sclerotic vessels which clinically manifests as light and often self-limiting bleeding both classic studies [3,11] and more recent summaries [8] confirm that this mechanism underlies the majority of pmb cases.

2. Endometrial Polyps

Endometrial polyps are benign localized overgrowths composed of endometrial glands fibrous stroma and characteristically thick-walled vessels histologically they may display simple cystic gland dilatation and are often covered by atrophic or functional epithelium these polyps are now recognized as an important cause of focal or recurrent pmb particularly as imaging and hysteroscopy enable better detection recent analyses such as the chaid decision tree study from 2021 highlight that larger polyp size and higher bmi are associated with a greater risk of atypia or malignancy within polyps underscoring the need for thorough histological evaluation [3,8].

3. Endometrial Hyperplasia

Endometrial hyperplasia develops due to persistent estrogen stimulation without the balancing effect of progesterone histologically it is marked by an increased density of endometrial glands compared to the surrounding stroma with the glands often appearing crowded and irregular in shape this condition is categorized into two types hyperplasia without atypia which generally carries a low propensity for further progression to malignancy and atypical hyperplasia which is associated with a markedly higher risk of cancerous transformation recent research indicates that endometrial hyperplasia is a significant contributing factor to postmenopausal bleeding particularly in women affected by obesity diabetes or metabolic syndrome [3,12,13].

4. Endometrial Carcinoma

Endometrial carcinoma most often presenting as endometrioid adenocarcinoma represents an important malignant etiology of postmenopausal bleeding microscopically it features complex glandular proliferation marked nuclear atypia numerous mitotic figures and evidence of stromal invasion often developing on a background of hyperplasia these cancers are strongly linked to prolonged exposure to endogenous or exogenous estrogen particularly in patients with additional risk factors like obesity and metabolic disease recent data emphasize that abnormal uterine bleeding remains the most common presenting symptom for endometrial carcinoma [3,11,12,13]

5. Other Benign Findings

Other benign histological patterns occasionally encountered include proliferative endometrium often associated with hormone replacement therapy use and secretory changes linked to exogenous hormones or residual ovarian function submucosal fibroids though benign smooth muscle tumors can also contribute to bleeding when they erode or ulcerate the endometrial surface while these findings are less common

recognizing them is essential for a complete histopathological assessment [3,8]

6. Cervical Pathology

Though less prevalent cervical lesions can be significant contributors to pmb cervical polyps typically consist of fibrous stroma covered by columnar epithelium and may bleed with minimal trauma in contrast cervical carcinoma most often squamous cell carcinoma displays malignant squamous nests keratinization or glandular features in adenocarcinoma variants importantly cervical cancer can cause pmb even when the endometrium itself is thin or appears normal on imaging highlighting the need for careful cervical evaluation [3,12].

V. HISTORY OF PRESENT ILLNESS

In evaluating a patient with postmenopausal bleeding, it is essential for clinicians to gather a complete and detailed history to help determine the underlying cause and confirm the patient's menopausal status.

Key components include:

Bleeding details: Gather information on when the bleeding began, its frequency, how long it lasts, how heavy it is, and the nature of the flow (e.g., spotting vs significant bleeding). Clarify whether the bleeding is spontaneous or triggered by actions such as sexual activity or wiping.

Associated symptoms: Document any additional symptoms, such as pelvic discomfort, fever, abnormal vaginal discharge, urinary urgency or pain, painful intercourse, or dryness, which could point to atrophic changes, infection, or possible malignancy [16,17].

Past Medical History

Several chronic medical conditions may predispose a patient to abnormal uterine bleeding, common contributors include obesity, diabetes, high blood pressure, PCOS, thyroid dysfunction, chronic pelvic infections, and bleeding disorders. These factors are also associated with an increased likelihood of endometrial hyperplasia or malignancy. Exposure to pelvic radiation or systemic diseases may also be relevant in postmenopausal bleeding [16,17].

Gynecologic History

A full menstrual and reproductive history should be taken, including age at menarche and menopause, the last menstrual period, and menstrual pattern. Early menarche (before age 12) and late menopause (after age 55) are associated with greater lifetime estrogen exposure and a higher risk for endometrial cancer. Include contraceptive use, number of pregnancies, Pap smear results, and any HPV testing history [16,17].

Surgical History

Previous gynecologic or pelvic surgeries—such as hysterectomy, oophorectomy, or endometrial procedures—should be reviewed. These may influence

bleeding patterns and help assess whether any functional endometrial tissue remains [16].

Social History

Discuss sexual behavior and screen for sexually transmitted infections. Record lifestyle habits, including tobacco use, alcohol consumption, and occupational exposure to carcinogens. Smoking is particularly associated with increased risk for cervical and bladder malignancies [16].

Family History

Ask about a family history of cancers, particularly those affecting the breast, uterus, ovary, colon, or urinary tract. Consider genetic cancer syndromes such as Lynch syndrome or Cowden syndrome in appropriate cases [16].

Medication History

Review current and past use of medications known to affect the endometrium, such as hormone replacement therapy, tamoxifen, or anticoagulants. Inquire about use of herbal products or supplements containing phytoestrogens, as these may also stimulate endometrial tissue and contribute to PMB [16,17].

VI. PHYSICAL EXAMINATION

A thorough physical examination is essential to identify clinical indicators of potential pathology.

- **Examination of External Genitalia:** The vulva and perineal region should be inspected for any noticeable changes in the skin, evidence of trauma, signs of atrophy, lesions, or abnormalities in the urethral area.
- **Speculum Examination:** This allows direct visualization of the vaginal canal and cervix to detect atrophic changes (such as pale, smooth mucosa and loss of rugae), polyps, prolapse, lesions, or active bleeding. Indicators of inflammation, including erythema, petechial bleeding, or abnormal discharge, should also be documented [16].
- **Bimanual Palpation:** The uterus and adnexal structures should be palpated to assess their size, shape, tenderness, mobility, and to check for any masses. The presence of cervical motion tenderness or pelvic organ prolapse should also be evaluated.
- **Rectovaginal Examination:** This may be performed when necessary to better evaluate posterior pelvic structures and the parametria.
- **General Physical Assessment:** Look for systemic manifestations such as pallor (indicative of anemia), lymphadenopathy, or abdominal distension, which may point to advanced or disseminated disease [16,17]

VII. EVALUATION

Evaluation of postmenopausal bleeding (PMB) starts with a detailed clinical history covering bleeding onset,

frequency, volume, and contributing risk factors such as obesity, diabetes, hypertension, and prior exposure to hormone replacement therapy or tamoxifen (14,15). A thorough pelvic examination follows: speculum inspection can identify cervical polyps, neoplastic lesions, or signs of vaginal atrophy, while bimanual palpation assesses uterine enlargement or adnexal masses (14). Although cervical cytology (Pap smear) remains part of routine evaluation, its sensitivity for diagnosing endometrial pathology is limited (15). Transvaginal ultrasound (TVUS) is the first-line imaging modality, enabling measurement of endometrial thickness and detection of focal lesions like polyps or submucosal fibroids (14,15). An endometrial thickness $\leq 4\text{--}5\text{ mm}$ is typically associated with low risk of malignancy, while greater thickness or irregular endometrial features warrant further evaluation (14). For diffuse thickening, office-based endometrial sampling (e.g., Pipelle biopsy) is commonly performed; if TVUS identifies focal abnormalities or is inconclusive, diagnostic hysteroscopy with targeted biopsy is preferred (14,16). Additional tools—including saline infusion sonohysterography (SIS) or MRI—can help assess complex cases (14,17). Importantly, clinicians should also consider and exclude other potential bleeding sources from the urinary or gastrointestinal tract to secure an accurate diagnosis and guide appropriate management (18). A flowchart illustrating the major steps in the evaluation of postmenopausal bleeding is presented in Fig. 2




Fig. 2: Flowchart depicting the systematic evaluation of postmenopausal bleeding

VIII. TREATMENT OF POSTMENOPAUSAL BLEEDING (PMB)

To accurately determine the cause of postmenopausal bleeding, doctors rely on a mix of physical exams, imaging tests, and tissue analysis. The most common reason for bleeding is **endometrial**

atrophy, particularly in women who aren't on hormone replacement therapy. In these situations, using local estrogen—such as vaginal creams, rings, or pessaries, can help rebuild the thinning uterine lining and reduce bleeding. If atrophy is confirmed and there are no signs of anything serious, no further treatment is typically needed. [7,19,21].

If the bleeding is due to **endometrial or cervical polyps**, the best approach is to **remove them completely**, preferably through **hysteroscopic polypectomy**. This method allows the doctor to remove the entire polyp while directly visualizing it and also provides a sample that can be examined accurately under a microscope. Dilation and curettage (D&C) is not the preferred option because it can miss small or localized growths. After removal, it's important to examine the tissue to rule out any signs of pre-cancer or cancer [3,8]. Treatment for **endometrial hyperplasia** depends on whether atypical (abnormal) cells are present or not. When there's no atypia, **progestin therapy** is usually recommended, either in the form of oral medication or an intrauterine device such as the **levonorgestrel-releasing IUS**. This hormone treatment helps slow down abnormal cell growth and needs to be followed up with endometrial sampling to track how well it's working. If **atypical hyperplasia** is found, especially in postmenopausal women, a **hysterectomy** is usually the recommended treatment because of the higher risk of it progressing to endometrial cancer. [4,19,21].

When **endometrial cancer** is detected, it's important to quickly refer the patient to a gynecologic oncologist for specialized care. The usual treatment involves **removing the uterus along with both ovaries and fallopian tubes through a total hysterectomy**. Depending on how advanced the cancer is, further treatment like radiation or chemotherapy may be required. Since postmenopausal bleeding often prompts early medical attention, many patients are diagnosed at an early stage when treatment is more effective and outcomes are generally better [4,8,14].

Although **cervical cancer** is a less common cause of postmenopausal bleeding, it should still be taken into account. Early stages can usually be treated with surgery, while more advanced cases often need a **combination of chemotherapy and radiation**. **Regular Pap smears and colposcopy** are important for assessing all women with postmenopausal bleeding, particularly if the uterine lining looks normal but the bleeding continues [4].

If the bleeding is related to **hormone-based medications** like **tamoxifen or HRT**, adjusting the dose or stopping the medication might help stop the bleeding. Women taking tamoxifen need regular checks of the uterine lining because the medication can raise the risk of developing polyps, thickening of the endometrium, and sometimes even cancer. [4,7].

When postmenopausal bleeding is caused by **non-gynecological issues** like infections, injuries, or

bleeding disorders, the treatment will vary based on the underlying problem. Infections are usually treated with antibiotics, injuries may need surgical repair, and bleeding disorders should be evaluated by a blood specialist. [4,21,7].

If a woman continues to experience bleeding or if the cause remains unclear even after an initial benign diagnosis, she should be re-evaluated. If symptoms come back or the **endometrial thickness increases beyond 5 mm**, especially in women who were initially managed without a biopsy, repeat ultrasound and endometrial sampling are advised[3,8].

IX. DIFFERENTIAL DIAGNOSIS

When evaluating postmenopausal bleeding (PMB), clinicians should be aware that the bleeding may not always originate from the genital tract. Similar symptoms can arise from non-gynaecologic sources, including the urinary or gastrointestinal systems, such as the urethra, bladder, or rectum. Therefore, it is essential to conduct a comprehensive assessment and consider other common conditions that could mimic PMB. (4,18)

1. Atrophic Endometrium/Vaginal Atrophy (4,18)
2. Endometrial Hyperplasia (18,19)
3. Endometrial Carcinoma (4,20)
4. Cervical Carcinoma (20)
5. Proliferative/Disordered Endometrium (4,18)
6. Endometrial and Cervical Polyps (20)
7. Exogenous Estrogen or Tamoxifen (20)
8. Ovarian Estrogen-Secreting Tumors (20)
9. Uterine Sarcoma and Other Rare Malignancies
10. Trauma or Foreign Bodies
11. Infections and Inflammation

X. PROGNOSIS

Postmenopausal bleeding (PMB) is a significant clinical symptom that often necessitates prompt evaluation, as it may signal underlying malignancy. Although many women experience PMB due to non-cancerous causes, the risk of serious pathology increases with age. Rubin's study identified that approximately 20% of PMB cases are attributed to cancer, with older age groups—particularly women over 80—showing the highest risk (4). Similarly, research by Paul et al. found a 14% malignancy rate among Indian women with PMB, with endometrial cancer being slightly more frequent than cervical cancer (21).

Transvaginal ultrasound is widely used to assess endometrial thickness. A threshold of ≥ 5 mm is generally considered indicative of possible endometrial pathology and warrants further diagnostic procedures. Epstein et al. highlight that a significant proportion of these women have focal lesions that require operative hysteroscopy for complete evaluation and treatment (8). Recent Indian studies suggest most PMB cases are benign. For instance, Rita et al. reported that 94% of

PMB cases were non-malignant, with conditions like atrophic endometrium and endometrial hyperplasia being most common. Nevertheless, 6% of cases were diagnosed with endometrial carcinoma (19). In contrast, earlier research by Schindler et al. revealed a considerably higher malignancy rate of 48%, many in advanced stages, emphasizing the need for timely investigation (3).

XI. COMPLICATIONS

- Delayed diagnosis, especially when bleeding is minimal and ignored (3).
- Missed pathology when relying on blind curettage instead of hysteroscopy (8).
- Repeat bleeding episodes due to residual or untreated lesions.
- Elevated risk in women with obesity, diabetes, or hypertension, owing to increased estrogen levels (4,19).
- Diagnostic challenges in women on hormone therapy, where symptoms may be masked (8).

XII. GUIDANCE FOR COUNSELLING PATIENTS WITH POSTMENOPAUSAL BLEEDING

When counselling a woman who presents with postmenopausal bleeding (PMB), it is essential to begin by clarifying that any vaginal bleeding after menopause is abnormal and should not be ignored. While many cases are caused by harmless conditions such as endometrial thinning (atrophy) or polyps, bleeding can also be a sign of more serious problems like cancer of the uterus or cervix. It is important to reassure the patient that although PMB can be alarming, early diagnosis allows for effective treatment, especially if the underlying cause is detected at an early stage [4,8,21]. During the discussion, patients should be encouraged to share specific details about the bleeding—when it began, how long it lasts, how often it occurs, whether it's light or heavy, and if it's triggered by sexual activity. A thorough history should include the use of hormone-based medications, such as hormone replacement therapy (HRT) or tamoxifen, and any use of alternative medicines like herbal products that mimic estrogen. Explain that even minimal spotting after menopause warrants medical evaluation and should not be dismissed [7].

Patients should be informed that diagnostic tests are necessary to identify the cause. These commonly include a pelvic examination, transvaginal ultrasound (TVS) to measure the endometrial thickness, and in some cases, a sample of the uterine lining (biopsy) or direct examination of the uterus using hysteroscopy. Reassure them that a thin endometrial

lining (4 mm or less) usually rules out cancer, while thicker linings may require more detailed evaluation. Explaining these steps helps reduce anxiety and builds trust in the process [3,4,8].

It's equally important to raise awareness about modifiable risk factors. Patients should be counselled about the increased risk of endometrial changes in women who are overweight, diabetic, hypertensive, or exposed to unopposed estrogen for long periods. Encourage them to adopt a healthy lifestyle, manage chronic conditions, and stay alert to any recurrence of symptoms. Emphasize the need for regular gynecologic check-ups, especially if they are on long-term hormonal treatment or have had PMB before [4,8,21].

Emotional support should be a key part of counselling. Many women feel anxious upon experiencing PMB due to fears about cancer. A calm, compassionate explanation of the condition and its possible causes, along with a step-by-step overview of the diagnostic and treatment plan, can help ease this stress. Encourage patients to ask questions and involve trusted family members if they wish, ensuring they feel supported and engaged in decisions about their care.

Finally, reinforce the message that prompt medical attention can make a significant difference. While some causes of PMB are serious, many are completely treatable. Early evaluation, proper testing, and ongoing follow-up will ensure the best outcomes. Counselling should aim to empower the patient with knowledge, comfort, and confidence to take charge of her health after menopause.

XIII. ENHANCED HEALTHCARE TEAM OUTCOMES IN POSTMENOPAUSAL BLEEDING CARE

The management of postmenopausal bleeding (PMB) has significantly improved due to a more collaborative and streamlined approach among healthcare providers. General physicians now serve as the first point of contact, recognizing symptoms early and referring patients without delay, which enhances diagnostic efficiency. Gynecologists, in coordination with radiologists and pathologists, utilize transvaginal ultrasonography (TVS) as a frontline diagnostic tool to assess endometrial thickness. This allows the team to differentiate between low-risk and high-risk patients effectively, minimizing the need for invasive procedures in those with reassuring ultrasound findings[8].

When further investigation is necessary, procedures like endometrial biopsy or hysteroscopy are conducted swiftly, enabling timely diagnosis of conditions like hyperplasia or malignancy. These interventions have become more accessible and are better integrated into care protocols[8].

Nurses and clinical pharmacists also contribute meaningfully by supporting patients with medication adherence, counseling on hormonal therapies, and ensuring regular follow-ups[21]. In confirmed cancer cases, early involvement of oncology specialists leads to prompt surgical and therapeutic interventions. The use of standardized clinical pathways has strengthened communication between departments, leading to more organized and effective patient care. Overall, these collaborative efforts have resulted in faster detection, optimized resource use, improved patient engagement, and more favorable outcomes in women presenting with PMB[4].

XIV. CLINICAL PHARMACIST'S ROLE IN POSTMENOPAUSAL BLEEDING (PMB) MANAGEMENT

Clinical pharmacists play an essential role in the team-based care of women with postmenopausal bleeding (PMB), supporting both the diagnosis and management process. One of their first and most important tasks is to carefully go through the patient's medications to identify anything that might be contributing to the bleeding. This often includes checking for hormone-related drugs like HRT and tamoxifen, blood thinners, and even herbal products that can mimic estrogen. Spotting these early helps the team understand what might be causing the bleeding and can often prevent unnecessary tests or procedures[7,8]. Pharmacists are also key in educating and guiding patients who are prescribed hormonal treatments, like estrogen or progestins, for conditions such as endometrial thinning or hyperplasia. They take the time to explain how the medication should be used, what benefits to expect, and what side effects to watch out for. They also check for any potential interactions with other medications the patient may be taking. In cases where progestins are used to treat endometrial hyperplasia, pharmacists help tailor the right dose and monitor how the patient is responding over time [7,6].

When surgery is needed like a hysteroscopy or hysterectomy, clinical pharmacists help manage the patient's medications before and after the procedure. They ensure ongoing treatments are handled safely, especially in patients with other health issues like diabetes or high blood pressure. Beyond individual care, pharmacists also help develop treatment plans, advise the care team, and promote safe medication use across the hospital. In rural or low-resource settings, their role becomes even more important as they often serve as a trusted support for patients throughout their treatment journey. Overall, their involvement helps ensure safer care, better outcomes, and improved communication across the healthcare team [4,21].

REFERENCES

- [1] Garg R. (2015). Postmenopausal bleeding. *O&G Magazine*, 54:1–4.
- [2] Vasudeva S, Baxi DA, Mishra A. (2022). A prospective study on postmenopausal bleeding-causes and its diagnosis using transvaginal ultrasound and hysteroscopy. *Int J Reprod Contracept Obstet Gynecol*, 11(9):2375–9.
- [3] Schindler AE, Schmidt G. (1980). Postmenopausal bleeding: a study of more than 1000 cases. *Maturitas*, 2:269–74.
- [4] Rubin SC. (1987). Postmenopausal bleeding: etiology, evaluation, and management. *Med Clin North Am*, 71(1):59–78.
- [5] van Maldegem LDRP, van der Zande JA, van Werkhoven LA, et al. (2024). Recurrent postmenopausal bleeding: pathological findings and predictive factors. *Acta Obstet Gynecol Scand*, 103(7):1283–91.
- [6] Begum J, Samal R. (2019). A clinicopathological evaluation of postmenopausal bleeding and its correlation with risk factors for developing endometrial hyperplasia and cancer: A hospital-based prospective study. *J Mid-life Health*, 10(4):179–83.
- [7] Garg R. (2015). Postmenopausal Bleeding. ResearchGate. Available at: <https://www.researchgate.net/publication/286392565>
- [8] Epstein E, Valentin L. (2004). Managing women with post-menopausal bleeding. *Best Pract Res Clin Obstet Gynaecol*, 18(1):125–43.
- [9] Smith-Bindman R, Weiss E, Feldstein V. (2004). How thick is too thick? When endometrial thickness should prompt biopsy in postmenopausal women without vaginal bleeding. *Obstet Gynecol*, 104(3):440–8.
- [10] Epstein E, Valentin L. (2004). Endometrial assessment in postmenopausal bleeding. *Best Pract Res Clin Obstet Gynaecol*, 18(1):125–43.
- [11] Wong M, Thanatsis N, et al. (2021). Risk of pre malignancy or malignancy in postmenopausal endometrial polyps: A CHAID decision tree analysis. *Diagnostics*, 11(6):1094. doi:10.3390/diagnostics11061094
- [12] Dubinskaya A, et al. (2022). Histopathological spectrum of postmenopausal endometrial lesions: review and update. *Diagnostics*, 12(9):2127. doi:10.3390/diagnostics12092127
- [13] Clarke MA, et al. (2022). Endometrial cancer presenting with postmenopausal bleeding: recent data and implications. *J Clin Oncol*, 40(16_suppl):e17557. doi:10.1200/JCO.2022.40.16_suppl.e17557
- [14] American College of Obstetricians and Gynecologists. (2020). ACOG Practice Bulletin No. 222: Evaluation of postmenopausal bleeding. *Obstet Gynecol*, 135(5):e193–e202. doi:10.1097/AOG.0000000000003771
- [15] Clark TJ, Stevenson H. (2021). Endometrial pathology in postmenopausal women with bleeding. *Best Pract Res Clin Obstet Gynaecol*, 78:22–32. doi:10.1016/j.bpobgyn.2021.01.006
- [16] Munro MG, Critchley HO, Fraser IS. (2011). The FIGO classification of causes of abnormal uterine bleeding in the reproductive years. *Fertil Steril*, 95(7):2204–8.
- [17] Bhatla N. (2018). Jeffcoate's Principles of Gynaecology. 9th ed. New Delhi: Jaypee Brothers Medical Publishers.
- [18] Zito A. (2014). Postmenopausal bleeding. *O & G Magazine*, 16(2).
- [19] Rita D, Kumar KS, Rithesh SK. (2016). Clinicopathological study of postmenopausal bleeding. *Int J Reprod Contracept Obstet Gynecol*, 5(11):3671–4.
- [20] Paul P, et al. (2023). Postmenopausal bleeding: clinicopathologic study in a tertiary care centre. *Int J Reprod Contracept Obstet Gynecol*, 12(2):401–7.
- [21] Paul P, Devi RP, Kom TT, Nath P, Devi TN, Longjam N. (2023). Evaluation of postmenopausal bleeding: A cross-sectional study. *Int J Reprod Contracept Obstet Gynecol*, 12(2):401–7.